曲妥珠单抗联合化疗治疗HER2阳性晚期胃癌临床有效率的Meta分析

Clinical efficiency of trastuzumab combined with chemotherapy on HER2 positive advanced gastric cancer: a meta analysis

目的通过Meta分析探讨曲妥珠单抗联合化疗对人表皮生长因子受体2(HER2)过度表达的晚期胃癌临床有效性,包括客观有效率(ORR)和疾病控制率(DCR)。方法以制定的检索策略为依据检索国内外相关研究,将收集到的临床观察数据分别计算出ORR和DCR以及相应的标准差,输入RevMan5.3进行二分类无对照率的Meta分析。结果 ORR和DCR整体效应比数比(OR)及95%可信区间(95%CI)分别为1.73[1.65~1.82]和2.30[2.17,2.44],差异有统计学意义(P<0.05)。结论曲妥珠单抗联合其他药物化疗治疗HER2阳性晚期胃癌的整体效应良好。

Objective To explore the clinical effectiveness of trastuzumab in combination with chemotherapy on HER2 （Human Epi- dermalgrowth Factor Receptor 2） overexpressed advanced gastric cancer through meta analysis investigate, including the ORR （objective response rate） and DCR （ disease - free control rate）. Methods Relevant research studies at home and abroad were retrieved based on the established re- trieval strategy. The collected clinical observation data were calculated for ORR and DCR and the corresponding standard deviation, which were in- put into the RevManS. 3 for non -comparative binary Meta- analysis. Results The total effect ratio （OR） of ORR and DCR and 95 % confi- dence interval （95%CI） wererespectivelyl.73[1.65-1.82] and2.3012.17,2.44],P 〈0.05. Conclusion The overall effect oftrastuzum- ab combined with chemotherapy with other drugs on HER2 positive advanced gastric cancer is good.